GLYCYX

Glycyx has a new approach to normalize immune function and inflammation in cancer and other severe illnesses. Our lead candidate for cancer improves the effectiveness of immuno-oncology therapies while also directly inhibiting tumor growth and metastasis. Glycyx was founded by scientists and an experienced management team that has built multiple successful life science companies. We are focused on proving the value of our lead drug candidate in immuno-oncology, while laying the biological groundwork for future programs in neurodegeneration, acute care, and ophthalmology. We are passionate about extending the quality and length of life.